Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term rollover study of dabrafenib and/or trametinib in pediatric patients
2018-004459-19Phase 4Active
- Sponsor
- Novartis
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dabrafenib + trametinib and trametinib in cancer (3 arms), sponsored by Novartis. Primary endpoint: Long-term safety. Started Jun 2019; status: active.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
cancer
Beyond the preview
Go deeper on 2018-004459-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004459-19.